Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment

• Published in: Scientific reports Vol. 12; no. 1; pp. 19067 - 7
• Main Authors: Fontes, Magda S. C., Dingemanse, Jasper, Halabi, Atef, Tomaszewska-Kiecana, Monika, Sidharta, Patricia N.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 09.11.2022; Nature Portfolio
• Subjects: 692/308; 692/308/153; 692/308/2779/109/1940; Area Under Curve; Endothelin Receptor Antagonists - adverse effects; Humanities and Social Sciences; Humans; Liver Diseases - drug therapy; Liver Diseases - metabolism; multidisciplinary; NCT; NCT04252495; Pyrimidines; Science; Science (multidisciplinary); Sulfonamides

The effect of moderate hepatic impairment on the pharmacokinetics (PK), safety, and tolerability of the dual endothelin receptor antagonist aprocitentan was clinically investigated as 25% of aprocitentan is cleared through the liver. Aprocitentan is in clinical development for the treatment of resis...